Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Pig Organ Transplantation: What Have We Learned So Far?

Xenotransplantation·2026
Same author

Clinical Xenotransplantation: A Suggested Next Step.

Xenotransplantation·2026
Same author

The Potential of Composite Pig Islets-Kidney Xenotransplantation to Cure Diabetes and Renal Failure: A Suggested Modified Approach.

Diabetes·2026
Same author

The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement-Dependent Cytotoxicity in Vitro.

Xenotransplantation·2026
Same author

High levels of IL-6 and IL-8 early after pig-to-nonhuman primate kidney xenotransplantation from α1,3-galactosyltransferase gene-knockout (GTKO) pigs.

Cytokine·2026
Same author

Is the intraportal or renal subcapsular space a preferable site for islet allo- and xeno-transplantation? A brief historical review.

Islets·2026

Related Experiment Video

Updated: May 7, 2026

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Published on: January 6, 2022

1.8K

Islet xenotransplantation from genetically engineered pigs.

Santosh Nagaraju1, Rita Bottino, Martin Wijkstrom

  • 1aThomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center bDivision of Immunogenetics, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Current Opinion in Organ Transplantation
|October 16, 2013
PubMed
Summary

Genetically engineered pig islets show promise for diabetes treatment in primates. Modifications reduce immune rejection and instant blood-mediated inflammatory reactions, paving the way for clinical trials.

More Related Videos

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model
07:34

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model

Published on: September 22, 2020

3.3K
A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model
06:52

A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model

Published on: November 4, 2025

580

Related Experiment Videos

Last Updated: May 7, 2026

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood
08:02

Characterization of Blood Outgrowth Endothelial Cells BOEC from Porcine Peripheral Blood

Published on: January 6, 2022

1.8K
Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model
07:34

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model

Published on: September 22, 2020

3.3K
A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model
06:52

A Standardized Pig to Macaque Heterotopic Heart Xenotransplantation Model

Published on: November 4, 2025

580

Area of Science:

  • Xenotransplantation research
  • Immunology
  • Endocrinology

Background:

  • Pigs are a potential source for islet transplantation to treat diabetes.
  • Porcine islets transplanted into nonhuman primates can reverse diabetes.
  • Challenges include instant blood-mediated inflammatory reaction (IBMIR) and T-cell mediated rejection.

Purpose of the Study:

  • To review the use of genetically modified porcine islets for transplantation.
  • To highlight strategies for overcoming immune barriers in xenotransplantation.
  • To assess the potential of engineered pig islets for clinical use.

Main Methods:

  • Genetic modification of pig islets to reduce immunogenicity.
  • Targeted transgene expression in pig beta cells using insulin promoter.
  • Deletion of pig antigenic targets to minimize humoral response.
  • Expression of human complement and coagulation regulatory proteins.
  • Strategies to mitigate T-cell mediated rejection.

Main Results:

  • Genetically modified islets show reduced IBMIR and improved survival.
  • Transgene expression in pig beta cells is achievable without affecting glucose metabolism.
  • Engineering strategies are being refined to enhance graft acceptance in primates.

Conclusions:

  • Genetically engineered pig islets offer significant advantages over wild-type islets.
  • Increasing experience with engineered islet transplantation in nonhuman primates.
  • These advancements support the future clinical application of porcine islet xenotransplantation for diabetes.